Dose normalization [Study Per­for­mance]

posted by Relaxation  – Germany, 2021-05-27 17:29 (1843 d 05:03 ago) – Posting: # 22373
Views: 5,795

❝ will not receive the actual dose, but will receive a smaller dose when assessing BD / BE (2x2x2) design)?


Hello yura.

I am sorry, but I am a little bit in a hurry and just wanted to start the answers here with one single comment.
As you are in a cross-over situation and assuming that the dose (BSA) of a subject will not change between periods, there is no need for a dose-adjustment with regard to the treatment comparison. Or the other way around: as you compare intraindividually the dose-adjustment would cancel out anyway.

Best regards!

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
117 visitors (0 registered, 117 guests [including 25 identified bots]).
Forum time: 22:33 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5